NOVITIUM PHARMA LLC
NOVITIUM PHARMA LLC (United States) holds 12 active US FDA Type II Drug Master Files and has DMF or CEP filings on record for 12 active ingredients. 6 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “NOVITIUM PHARMA LLC: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/novitium-pharma-llc
Overview
NOVITIUM PHARMA LLC is an active pharmaceutical ingredient (API) supplier with 12 active FDA Type II Drug Master Files, covering BETAINE ANHYDROUS; CARGLUMIC ACID; DAPSONE USP; DIAZOXIDE USP; DICHLORPHENAMIDE USP; FLUDROCORTISONE ACETATE USP.
Core services & business areas
Active ingredients with DMF or CEP filings
Substances for which NOVITIUM PHARMA LLC holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.
API / Drug Master Files
NOVITIUM PHARMA LLC holds 12 active (12 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- FLUDROCORTISONE ACETATE USPActive2020-06-09
- BETAINE ANHYDROUSActive2020-03-12
- METHYLTESTOSTERONE USPActive2019-12-17
- DICHLORPHENAMIDE USPActive2019-12-10
- LEVORPHANOL TARTRATE USPActive2018-12-31
- CARGLUMIC ACIDActive2018-12-07
- OXANDROLONE USPActive2017-10-28
- THIOTHIXENE USPActive2017-07-21
- PRAZOSIN HYDROCHLORIDE USPActive2017-06-16
- DIAZOXIDE USPActive2017-01-27
- NITISINONEActive2017-01-02
- DAPSONE USPActive2013-12-13
FDA compliance signals
6 FDA enforcement records linked to this company.
- recall — Class III2024-04-24
Failed Impurities/Degradation Specifications
- recall — Class III2024-03-27
Cross Contamination with Other Products:(mycophenolate mofetil).
- recall — Class II2019-11-20
CGMP Deviations: Presence of NDMA impurity detected in product.
- recall — Class II2019-11-20
CGMP Deviations: Presence of NDMA impurity detected in product.
- recall — Class II2019-11-20
CGMP Deviations: Presence of NDMA impurity detected in product.
- recall — Class II2019-11-20
CGMP Deviations: Presence of NDMA impurity detected in product.
Is this NOVITIUM PHARMA LLC?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.